ABSTRACTBackgroundWhen coronavirus disease 2019 (COVID‐19) vaccines first became available, pregnancy and lactation data were lacking. This void was often filled by misinformation. Even as data about pregnancy outcomes following COVID‐19 vaccination began to emerge, the public was often unsure how to interpret the information, and many pregnant women remained unclear on whether to get vaccinated. MotherToBaby and Centers for Disease Control and Prevention (CDC) quickly partnered to direct the public to MotherToBaby, a nationwide teratogen information service, for free and confidential discussions about COVID‐19 vaccines in pregnancy and lactation. This paper describes the partnership between MotherToBaby and CDC and the resulting COVID‐19 vaccine inquiries received.MethodsAggregate, deidentified data were extracted from a centralized database utilized by MotherToBaby to capture information about exposure inquiries. The data include exposure topics, caller characteristics, and specific questions about COVID‐19 vaccination.ResultsBetween March 1, 2021 and February 28, 2023, MotherToBaby answered 11,064 questions about COVID‐19 vaccines. Most (68.5%) were related to vaccine safety, with common safety‐related themes including perceived haste in vaccine development, hesitancy about mRNA technology, and concerns about infertility, miscarriage, and long‐term effects on the child. Lessons learned include the essential role of partnerships to educate the public during emergencies, the importance of building staff capacity during nonemergency times, and the need for one‐on‐one conversations to counter vaccine misinformation.ConclusionsDuring the COVID‐19 pandemic, MotherToBaby met a critical need by providing individualized, evidence‐based information to the public. During future public health emergencies, teratogen information services are uniquely suited to provide unbiased information about the risks and benefits of vaccines and other exposures.

01 Mar 2025·Nursing & Health Sciences

Nursing and Midwifery Students' COVID‐19 Vaccine Regrets and Future Vaccination Intentions: A Mixed Methods Study

Article

Author: Bozhan Tayhan, Esra ; Tayhan, Ali ; Şahin Büyük, Damla

ABSTRACTRegret over COVID‐19 vaccine decisions is a post‐pandemic phenomenon that needs further research. This mixed‐method research was conducted to examine nursing‐midwifery students' COVID‐19 vaccine decision regret and their intention to get vaccinated in the next pandemic. The research includes quantitative and qualitative research processes. In the first phase, a quantitative (cross‐sectional) study was conducted, collecting data from 602 participants who met the inclusion criteria. In the second phase, semi‐structured interviews were conducted with 16 participants. Data were collected using the Decision Regret Scale and semi‐structured interview form. Data were analyzed using Student's t‐test, one‐way anova test, and inductive content analysis, and reported using Good Reporting of a Mixed Methods Study. In the study, it was determined that 96.3% of the participants had received the COVID‐19 vaccine and 50.0% regretted getting vaccinated. As a result of the analysis of qualitative data, the following themes emerged that could reveal the reasons for vaccine regret; forced compliance, a strange pandemic, unknown effects, and vaccine hesitancy. Students' experiences in the COVID‐19 pandemic have the potential to increase negative attitudes towards their vaccines.

01 Dec 2024·Health Science Reports

COVID‐19 Vaccine Uptake and Associated Factors Among Persons With Disabilities in Ghana's Ashanti Region

Article

Author: Ampomah, Irene G. ; Seidu, Abdul‐Aziz ; Emeto, Theophilus I.

ABSTRACTBackgroundPersons with disabilities (PWD) are often marginalized and face barriers to accessing health services. This study aimed to examine the COVID‐19 vaccine uptake and its predictors among PWDs in the Ashanti region of Ghana, where about 17% of the population has some form of disability.MethodsA cross‐sectional survey was conducted among 402 PWDs in two districts of the Ashanti Region of Ghana from December 2021 to March 2022. Data were collected using a pretested structured questionnaire and analyzed using descriptive (frequencies and percentages) and inferential statistics (binary logistic regression).ResultsThe majority (68.7%) of the respondents had received the COVID‐19 vaccine. The vaccine uptake was significantly higher among PWDs with visual impairments (aOR = 1.81; 95% CI = 1.07–3.09; p = 0.028), older age groups (aOR = 4.95; 95% CI = 1.86–13.21; p = 0.001 for those aged 60 and above), those with junior high school level of education (aOR = 2.21; 95% CI = 1.05–4.64; p = 0.036), and those who were employed (aOR = 2.07; 95% CI = 1.07–3.99; p = 0.031), compared to their respective reference groups.ConclusionThe study revealed a moderate level of COVID‐19 vaccine uptake among PWDs in the Ashanti region, which may indicate some positive attitudes towards the prevention of the virus. However, there were disparities in the vaccine uptake by disability type, age, education, and employment status, which suggest the need for tailored interventions to address the specific needs and preferences of different subgroups of PWDs. The study also provides a basis for further research on the factors influencing COVID‐19 vaccine acceptance among PWDs in Ghana and other similar settings. To enhance the vaccine coverage and equity among the marginalized groups in the region, more practical and inclusive strategies are needed to overcome the barriers and challenges faced by PWDs in accessing the COVID‐19 vaccine.

News (Medical) associated with COVID-19 vaccine (TechnoVax)

28 Apr 2025

·endpts.com

Vaxart says it can resume next-gen Covid work, will screen participants for oral vaccine trial

Vaxart said a stop-work order has been lifted on its next-generation Covid-19 vaccine efforts planned under a Biden-era initiative, allowing it to screen participants for a large mid-stage trial to test its oral vaccine candidate. The company was one of at least three developers to receive stop-work orders related to Project NextGen, an initiative funded by BARDA to advance new Covid-19 vaccines. Vaxart said in a securities filing that it received notice last Thursday “that the stop work order had been lifted and that the Company may resume incurring costs, participating in meetings, and communicating with the Government” regarding the project award. Vaxart said the message came from Advanced Technology International, which partnered with BARDA to manage a program for supporting medical countermeasures. Vaxart said the notice “required further discussion between the Company and BARDA regarding costs, timelines, and regulatory pathway agreement.” After receiving the notice, the company said it had a virtual meeting with BARDA “wherein the Company was told that it could proceed with screening for the 10,000 participant portion” of a planned Phase 2b trial testing Vaxart’s oral vaccine candidate against a currently approved mRNA vaccine. “The Company also intends to continue discussions with BARDA regarding the plan for dosing participants and will provide further updates as appropriate,” Vaxart said. An HHS official confirmed that Vaxart’s stop-work order has been lifted, but said no final decision has been made on other stop-work orders received by GeoVax and CastleVax. CastleVax CEO Michael Egan told Endpoints News on Monday that the company had not received a lift notice regarding its stop-work order. CastleVax is working on an intranasal Covid-19 vaccine candidate, and Egan previously told Endpoints that it intends to continue developing the vaccine on its own. GeoVax, which also announced earlier this month that it had received a stop-work order, did not immediately respond to a request for comment on Monday. “Vaxart thanks the U.S. Department of Health and Human Services (HHS) for its thorough review of our COVID-19 oral vaccine candidate and looks forward to continuing its collaboration with HHS and other government partners,” a Vaxart spokesperson said on Monday. Editor’s Note: This story has been updated to include comment from an HHS official.

VaccinemRNAPhase 2Emergency Use Authorization

100 Deals associated with COVID-19 vaccine (TechnoVax)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Preclinical	United States	TechnoVax, Inc.	15 Jan 2021
COVID-19	Preclinical	United States	The CUNY School of Medicine	15 Jan 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

COVID-19 vaccine (TechnoVax)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation